Healios K.K. (OTCMKTS:HLOSF – Get Free Report) is anticipated to release its resultson Wednesday, May 13th. Analysts expect Healios K.K. to post earnings of ($0.0702) per share and revenue of $0.1730 million for the quarter.
Healios K.K. Price Performance
OTCMKTS HLOSF opened at $2.20 on Tuesday. The business’s 50 day moving average price is $2.39 and its 200-day moving average price is $2.50. Healios K.K. has a fifty-two week low of $1.90 and a fifty-two week high of $4.45.
Healios K.K. Company Profile
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
Further Reading
- Five stocks we like better than Healios K.K.
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
